US2023173173A1PendingUtilityA1

Event detection for drug delivery system

Assignee: INSULET CORPPriority: Oct 11, 2018Filed: Jan 27, 2023Published: Jun 8, 2023
Est. expiryOct 11, 2038(~12.2 yrs left)· nominal 20-yr term from priority
G16H 40/63A61B 5/02055A61M 2205/502A61B 2562/0219A61M 2230/201A61M 2005/1585A61M 2205/18A61M 5/1723A61B 5/4839G16H 20/17A61M 2005/14252A61M 5/158A61M 5/14244A61B 5/0024A61M 2205/52A61M 2005/14208A61M 2205/3576A61B 5/14532A61M 31/002
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.

Claims

exact text as granted — not AI-modified
1 .- 20 . (canceled) 
     
     
         21 . An on-body drug delivery device, comprising:
 a communication interface operable to communicate with a glucose sensor;   an inertial measurement unit comprising at least one of an accelerometer or a gyroscope; and   a controller, at least a portion of which is implemented in circuitry coupled to the communication interface and the inertial measurement unit, wherein the controller is operable to:
 determine that glucose measurements received from the communication interface are changing; 
 generate an alert requesting confirmation of a change to drug delivery; 
 receive, via the inertial measurement unit, an indication responsive to the requested confirmation; and 
 determine a response based on the received indication. 
   
     
     
         22 . The on-body drug delivery device of  claim 21 , wherein the inertial measurement unit is further operable to detect an occurrence of one or more taps or touches on the on-body drug delivery device, and the controller is further operable to determine whether the occurrence of the one or more taps or touches on the on-body drug delivery device matches a pre-programmed sequence of taps or touches. 
     
     
         23 . The on-body drug delivery device of  claim 22 , wherein the controller is further operable to:
 receive, from the inertial measurement unit, the detected occurrence of the one or more taps or touches; and   generate a notification confirming a bolus delivery has been or will be delivered.   
     
     
         24 . The on-body drug delivery device of  claim 21 , wherein the controller is further operable to:
 determine that the received indication is confirmation that a meal has been ingested.   
     
     
         25 . The on-body drug delivery device of  claim 21 , wherein the controller, when generating the alert requesting confirmation of a change to drug delivery, is operable to:
 forward a message, via the communication interface, to a remote device.   
     
     
         26 . The on-body drug delivery device of  claim 21 , wherein the controller, when determining the response based on the received indication, is further operable to:
 cause a change to drug delivery; and   generate a notification that a change to drug delivery has been undertaken.   
     
     
         27 . The on-body drug delivery device of  claim 21 , wherein the controller, based on the determined response, is further operable to:
 cause a vibration to be emitted from the on-body drug delivery device indicating that a bolus injection is needed.   
     
     
         28 . The on-body drug delivery device of  claim 27 , wherein the controller is further operable to:
 receive, via the inertial measurement unit, a further indication confirming delivery of the bolus injection.   
     
     
         29 . The on-body drug delivery device of  claim 21 , wherein the alert requesting confirmation is an audible alert. 
     
     
         30 . An on-body drug delivery device, comprising:
 a drug reservoir operable to hold a liquid drug;   an inertial measurement unit operable to detect taps or touches on the on-body drug delivery device;   an output device operable to output alerts, and   a controller, wherein the controller is operable to:   generate, via the output device, an alert that a change to drug delivery is needed;   receive, via the inertial measurement unit, a signal regarding a sequence of one or more taps or touches to the on-body drug delivery device; and   compare the sequence of one or more taps or touches to the on-body drug delivery device to one or more pre-programmed sequences; and   based on the comparison, carry out a change to drug delivery if the sequence of one or more taps or touches to the on-body drug delivery device matches a pre-programmed sequence that corresponds to the change to drug delivery.   
     
     
         31 . The on-body drug delivery device of  claim 30 , wherein the change to drug delivery is a bolus injection. 
     
     
         32 . The on-body drug delivery device of  claim 30 , wherein the alert is an indication that a glucose level has risen and the change to drug delivery is a bolus injection of the liquid drug. 
     
     
         33 . The on-body drug delivery device of  claim 30 , wherein the output device comprises:
 a speaker that is operable to output the generated alert as an audible alert.   
     
     
         34 . The on-body drug delivery device of  claim 30 , wherein the output device comprises:
 a vibration device that is operable to output the generated alert as a tactile indicator.   
     
     
         35 . The on-body drug delivery device of  claim 30 , further comprising:
 a communication interface operable to receive communications via a wireless communication link, wherein the communication interface is coupled to the controller.   
     
     
         36 . The on-body drug delivery device of  claim 35 , wherein the communication interface is further operable to:
 provide the controller with glucose measurements received by the communication interface from a glucose monitor.   
     
     
         37 . The on-body drug delivery device of  claim 36 , wherein the controller is further operable to:
 receive the glucose measurements from the communication interface; and   determine based on the received glucose measurements whether to generate the alert that a change to drug delivery is needed.   
     
     
         38 . A drug delivery system, comprising:
 a glucose sensor including a sensing device and a communication device, wherein the sensing device is operable to measure glucose and the communication device is operable to transmit data indicative of the measured glucose; and   an on-body drug delivery device including:   a drug reservoir operable to hold a liquid drug;   an inertial measurement unit operable to detect taps or touches on the on-body drug delivery device; and   a controller, wherein the controller is operable to:   receive the data indicative of the measured glucose;   based on the received data, generate a haptic or audible alert;   receive, via the inertial measurement unit, data indicative of a sequence of one or more taps or touches on the on-body drug delivery device; and   generate a response based on the received data indicative of the sequence of one or more taps or touches on the on-body drug delivery device.   
     
     
         39 . The drug delivery system of  claim 38 , the on-body drug delivery device further comprising:
 a speaker or a vibration device, wherein the speaker is operable to output the audible alert, and the vibration device is operable to output the haptic alert.   
     
     
         40 . The drug delivery system of  claim 38 , wherein the alert is an indication that a glucose level has risen and the response is a bolus injection of the liquid drug.

Join the waitlist — get patent alerts

Track US2023173173A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.